Macular Hole Surgery With and Without Internal Limiting Membrane Peeling：A Systematic Review and Meta-analysis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01687829

Enrollment

400

Registered

2012-09-19

Start date

2013-01-31

Completion date

2014-05-31

Last updated

2014-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Holes

Keywords

Macular Holes, Internal limiting membrane, peeling, Surgery

Brief summary

Since Kelly and Wendel first reported successful closure of idiopathic macular holes (MH) by vitrectomy in 1991, many surgical modifications have been made to improve the anatomical and visual outcomes of this surgery. Recently, internal limiting membrane (ILM) peeling has become used widely as an adjunctive procedure during MH surgery because the removal of ILM is thought to reduce the tangential traction on the macula, a major factor in the pathogenesis of idiopathic macular holes. However, the role of ILM peeling in macular hole surgery is not yet well defined. To the best of our knowledge, there is no meta-analysis on comparison of the efficacy of ILM peeling and suture for MH surgery. This study reviewed the published literature comparing surgical results with and without ILM peeling and and performed a meta-analysis to determine whether there is any benefit or detriment anatomically and/or visually.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Eligible participants are those with idiopathic FTMH in stages 2-3, of less or equal than 18 months duration (based on symptoms reported by the patient) and with a visual acuity equal to or worse than 20/40 in the study eye.

Exclusion criteria

* Patients with idiopathic FTMH stages 2-3 but longer than 18 months duration or with other causes of decreased vision (e.g. corneal scarring, age-related macular degeneration, diabetic retinopathy, glaucoma if central and/or paracentral absolute visual field defects are present) and * Those with FTMH related to high myopia (\> 6 dioptres) or trauma will be excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
Anatomic Success rate	12 months	Anatomic success defined as a closed hole without a visible edge or a flat hole without a rim of subretinal fluid.
Functional Success Rate	12 month	Functional Success defined as an improvement of 2 or more Snellen BCVA.

Secondary

Measure	Time frame	Description
Best-corrected visual acuity	12 month	All Snellen BCVA were converted to logarithm of the minimum angle of resolution (logMAR) BCVA
Complications	12 months	Such as elevated intraocular pressure,retinal tear,rhegmatogenous retinal detachment

Countries

China

Outcome results